Publication

Serum MMP-3 Level as a Biomarker for Monitoring and Predicting Response to Etanercept Treatment in Ankylosing Spondylitis

Arends, S., van der Veer, E., Groen, H., Houtman, P. M., Jansen, T. L. T. A., Leijsma, M. K., Bijzet, J., Limburg, P. C., Kallenberg, C. G. M., Spoorenberg, A. & Brouwer, E., Aug-2011, In : Journal of Rheumatology. 38, 8, p. 1644-1650 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Arends_2011_J_Rheumatol.pdf

    Final publisher's version, 245 KB, PDF document

DOI

Objective. To investigate whether level of serum matrix metalloproteinase-3 (MMP-3) can serve as a biomarker for monitoring and predicting response to etanercept treatment in patients with ankylosing spondylitis (AS) in daily clinical practice.

Methods. Ninety-two consecutive AS outpatients with active disease who started etanercept treatment were included in this longitudinal observational study. Clinical data were collected prospectively at baseline and after 3 and 12 months of treatment. At the same timepoints, serum MMP-3 levels were measured retrospectively by ELISA.

Results. Since baseline serum MMP-3 levels were significantly higher in male compared to female patients with AS, data analysis was split for gender. Changes in serum MMP-3 levels after etanercept treatment correlated positively with changes in clinical assessments of disease activity and physical function in both male and female patients. Receiver operating characteristic analysis in male patients showed that baseline serum MMP-3 levels had poor accuracy (AUC <0.7) to discriminate between Assessments in Ankylosing Spondylitis 20 (ASAS20) or ASAS40 responders and nonresponders after 3 or 12 months of treatment. The accuracy of change in serum MMP-3 levels from baseline to 3 months in predicting response after 3 or 12 months of treatment was poor for ASAS40 (AUC <0.7) or moderate for ASAS20 (AUC = 0.752 and 0.744, respectively), and was not superior to the accuracy of change in the currently used objective biomarkers, erythrocyte sedimentation rate and C-reactive protein.

Conclusion. Although significant changes in serum MMP-3 levels were found after etanercept treatment, data analysis indicates that serum MMP-3 levels are not very useful for monitoring and predicting response to etanercept treatment in patients with AS in daily clinical practice. (First Release June 1 2011; J Rheumatol 2011;38:1644-50; doi :10.3899/jrheum.101128)

Original languageEnglish
Pages (from-to)1644-1650
Number of pages7
JournalJournal of Rheumatology
Volume38
Issue number8
Publication statusPublished - Aug-2011

    Keywords

  • ANKYLOSING SPONDYLITIS, SERUM MMP-3 LEVELS, BIOMARKERS, PREDICTORS, ETANERCEPT TREATMENT, ERYTHROCYTE SEDIMENTATION-RATE, NECROSIS-FACTOR-ALPHA, C-REACTIVE PROTEIN, MATRIX-METALLOPROTEINASE EXPRESSION, EARLY RHEUMATOID-ARTHRITIS, DISEASE-ACTIVITY, STRUCTURAL DAMAGE, TRIAL, MATRIX-METALLOPROTEINASE-3, DESTRUCTION

ID: 2505639